130 related articles for article (PubMed ID: 28392461)
81. Targeting the MMP-14/MMP-2/integrin α
Yosef G; Arkadash V; Papo N
J Biol Chem; 2018 Aug; 293(34):13310-13326. PubMed ID: 29986882
[TBL] [Abstract][Full Text] [Related]
82. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
Kiesgen S; Arndt MAE; Körber C; Arnold U; Weber T; Halama N; Keller A; Bötticher B; Schlegelmilch A; Liebers N; Cremer M; Herold-Mende C; Dyckhoff G; Federspil PA; Jensen AD; Jäger D; Kontermann RE; Mier W; Krauss J
Cancer Lett; 2015 Feb; 357(1):364-373. PubMed ID: 25434798
[TBL] [Abstract][Full Text] [Related]
83. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
[TBL] [Abstract][Full Text] [Related]
84. Construction of An Orthotopic Xenograft Model of Non-small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities.
Xu Z; Huang Y; Zhu Y; Pei X; Lu Y; Zhao S; Guo X
J Vis Exp; 2024 May; (207):. PubMed ID: 38801268
[TBL] [Abstract][Full Text] [Related]
85. Targeting antitumor effect of rhTNF-α fusion protein mediated by matrix metalloproteinase-2.
Shao X; Ren H; Wang YL; Wang F; Hou G; Huang DN
Oncol Rep; 2015 Feb; 33(2):810-8. PubMed ID: 25421954
[TBL] [Abstract][Full Text] [Related]
86. [Optimization of the preparation process for fusion protein Fv-LDP that composes lidamycin apoprotein and single-chain Fv antibody directed against type IV collagenase].
Gao RJ; Zhao CY; Li DD; Zhen YS
Yao Xue Xue Bao; 2013 Oct; 48(10):1563-9. PubMed ID: 24417083
[TBL] [Abstract][Full Text] [Related]
87. Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma.
Zhang Q; Liu X; Li C; Liao D; Ouyang Z; Zheng J; Song X
Oncol Lett; 2013 Sep; 6(3):801-806. PubMed ID: 24137414
[TBL] [Abstract][Full Text] [Related]
88. Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors.
Khalil HH; El-Sheshtawy MM; Khattab SN; Abu-Serie MM; Shehat MG; Teleb M; Haiba NS
Bioorg Chem; 2024 Mar; 144():107155. PubMed ID: 38306827
[TBL] [Abstract][Full Text] [Related]
89. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
[TBL] [Abstract][Full Text] [Related]
90. A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index.
Yang Y; Guo R; Chen Q; Liu Y; Zhang P; Zhang Z; Chen X; Wang T
Biotechnol Lett; 2018 May; 40(5):789-795. PubMed ID: 29600425
[TBL] [Abstract][Full Text] [Related]
91. An EGF receptor-targeting amphinase recombinant protein mediates anti-tumor activity in vitro and in vivo.
Shen R; Ye D; Huang Q; Li J; Wang Q; Fei J
Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):391-398. PubMed ID: 29566107
[TBL] [Abstract][Full Text] [Related]
92. Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer.
Ma X; Phi Van V; Kimm MA; Prakash J; Kessler H; Kosanke K; Feuchtinger A; Aichler M; Gupta A; Rummeny EJ; Eisenblätter M; Siveke J; Walch AK; Braren R; Ntziachristos V; Wildgruber M
Neoplasia; 2017 Jan; 19(1):8-16. PubMed ID: 27940248
[TBL] [Abstract][Full Text] [Related]
93. Antitumor and antimetastatic activities of Rhizoma Paridis saponins.
Man S; Gao W; Zhang Y; Yan L; Ma C; Liu C; Huang L
Steroids; 2009; 74(13-14):1051-6. PubMed ID: 19699217
[TBL] [Abstract][Full Text] [Related]
94. Site-specific PEGylation of lidamycin and its antitumor activity.
Li L; Shang B; Hu L; Shao R; Zhen Y
Acta Pharm Sin B; 2015 May; 5(3):264-9. PubMed ID: 26579455
[TBL] [Abstract][Full Text] [Related]
95. Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro.
Wen Z; Jia Q; Kang X; Lou Y; Zou L; Yang J; Gao J; Han L; Li X
Anticancer Drugs; 2017 Jan; 28(1):31-39. PubMed ID: 27759573
[TBL] [Abstract][Full Text] [Related]
96. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.
Shirian J; Arkadash V; Cohen I; Sapir T; Radisky ES; Papo N; Shifman JM
FEBS Lett; 2018 Apr; 592(7):1122-1134. PubMed ID: 29473954
[TBL] [Abstract][Full Text] [Related]
97. Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
Hayun H; Arkadash V; Sananes A; Arbely E; Stepensky D; Papo N
Bioconjug Chem; 2022 May; 33(5):795-806. PubMed ID: 35446024
[TBL] [Abstract][Full Text] [Related]
98. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.
Hristodorov D; Mladenov R; Pardo A; Pham AT; Huhn M; Fischer R; Thepen T; Barth S
Br J Cancer; 2013 Sep; 109(6):1570-8. PubMed ID: 23942071
[TBL] [Abstract][Full Text] [Related]
99. Cinnamamide, an antitumor agent with low cytotoxicity acting on matrix metalloproteinase.
Jiang X; Zhen Y
Anticancer Drugs; 2000 Jan; 11(1):49-54. PubMed ID: 10757563
[TBL] [Abstract][Full Text] [Related]
100. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
